<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369850</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000482381</org_study_id>
    <secondary_id>IBCSG-18-98-BS</secondary_id>
    <secondary_id>EU-20623</secondary_id>
    <secondary_id>IBCSG-1-98-BS</secondary_id>
    <secondary_id>NOVARTIS-2026703019</secondary_id>
    <nct_id>NCT00369850</nct_id>
  </id_info>
  <brief_title>Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98</brief_title>
  <official_title>Investigating Bone Density and Bone Loss Without Baseline Information</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help
      measure bone loss in women receiving treatment for breast cancer. The test results may help
      doctors plan better treatment.

      PURPOSE: This phase III trial is studying bone density and bone loss in postmenopausal women
      with breast cancer receiving treatment in clinical trial IBCSG-1-98.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the effects on bone mineral density (BMD) in the L2-L4 (posterio-anterior)
           region of the spine and hip by assessing bone density in postmenopausal women with
           breast cancer receiving treatment on protocol IBCSG-1-98.

        -  Compare the incidence of radiological gross changes and fractures identified from spine
           x-rays (T4-L4) in these patients (in groups 1 and 2).

        -  Use longitudinal BMD measurements to estimate a linear rate of bone loss based on mixed
           effect models.

        -  Identify serum markers for bone loss to determine how they correlate with osteoporosis,
           microfractures, clinical fractures, and breast cancer-related bone events.

      OUTLINE: This is a multicenter study and a substudy of protocol IBCSG-1-98. Patients are
      assigned to 1 of 3 groups according to the length of treatment they have undergone on
      protocol IBCSG-1-98.

        -  Group 1 (prior to or at the end of the second year of treatment on protocol IBCSG-1-98):
           Patients undergo bone mineral density (BMD) testing of the L2-L4 spine and hip at
           baseline and years 1, 2, 3, and 4 from baseline. They also undergo x-rays of the T4-L4
           spine at baseline and years 1, 3, and 4 from baseline.

        -  Group 2 (after 2 years but before the end of the third year of treatment on protocol
           IBCSG-1-98): Patients undergo BMD testing of the L2-L4 spine and hip at baseline and
           years 1, 2, and 3 from baseline. They also undergo x-rays of the T4-L4 spine at baseline
           and years 2 and 3 from baseline.

        -  Group 3 (after 3 years but before the end of the fifth year of treatment on protocol
           IBCSG-1-98): Patients undergo BMD testing of the L2-L4 spine and hip at baseline and
           years 1 and 2 from baseline (for patients in 4th year of treatment) or year 1 from
           baseline (for patients in 5th year of treatment).

      Patients undergo blood collection at baseline and periodically during study for biomarker
      correlative study.

      PROJECTED ACCRUAL: A total of 660 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative percent change of bone mineral density (BMD) form baseline to after 2, 3, 4, or 5 years of treatment on protocol IBCSG-1-98</measure>
    <time_frame>5 years after randomisation to BIG 1-98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery of BMD at 1 year after the completion of treatment on protocol IBCSG-1-98</measure>
    <time_frame>6 years after randomisation to BIG 1-98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with BMD below the absolute threshold value for osteoporosis</measure>
    <time_frame>5 years after randomisation to BIG 1-98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative percent change in markers of bone resorption from baseline to after 2, 3, 4, or 5 years of treatment on protocol IBCSG-1-98</measure>
    <time_frame>5 years after randomisation to BIG 1-98</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery of the markers of bone resorption at 1 year after the completion of treatment on protocol IBCSG-1-98</measure>
    <time_frame>6 years after randomisation to BIG 1-98</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">458</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Tamoxifen for 5 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with tamoxifen for 5 years after randomisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole for 5 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with letrozole for 5 years after randomisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen 2 years plus letrozole 3 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole 2 years plus tamoxifen 3 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.</description>
    <arm_group_label>Tamoxifen for 5 years</arm_group_label>
    <arm_group_label>Letrozole for 5 years</arm_group_label>
    <arm_group_label>Tamoxifen 2 years plus letrozole 3 years</arm_group_label>
    <arm_group_label>Letrozole 2 years plus tamoxifen 3 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual energy X-ray absorptiometry (DEXA)</intervention_name>
    <description>Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.</description>
    <arm_group_label>Tamoxifen for 5 years</arm_group_label>
    <arm_group_label>Letrozole for 5 years</arm_group_label>
    <arm_group_label>Tamoxifen 2 years plus letrozole 3 years</arm_group_label>
    <arm_group_label>Letrozole 2 years plus tamoxifen 3 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spine X-ray</intervention_name>
    <description>Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.</description>
    <arm_group_label>Tamoxifen for 5 years</arm_group_label>
    <arm_group_label>Letrozole for 5 years</arm_group_label>
    <arm_group_label>Tamoxifen 2 years plus letrozole 3 years</arm_group_label>
    <arm_group_label>Letrozole 2 years plus tamoxifen 3 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of breast cancer

               -  Resected disease

          -  Enrolled on protocol IBCSG-1-98

               -  Receiving adjuvant endocrine therapy comprising 1 of the following regimens:

                    -  Letrozole

                    -  Tamoxifen

                    -  Letrozole after 2 years of tamoxifen

                    -  Tamoxifen after 2 years of letrozole

               -  Not yet completed 5 years of treatment

          -  No breast cancer recurrence or second primary cancer

          -  No known, symptomatic bone disease, including osteomalacia or osteogenesis imperfecta

          -  No prior registration to protocol IBCSG-1-98 Bone Mineral Density substudy

          -  Hormone receptor status:

               -  Estrogen receptor-positive and/or progesterone receptor-positive tumor

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal

          -  No uncontrolled thyroid or parathyroid disease, Cushing's disease, or other pituitary
             diseases

          -  No malabsorption syndrome or clinically relevant vitamin D deficiency

          -  No patients for whom the bone density determination is impossible

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 1 year since prior and no concurrent anticonvulsants

          -  More than 6 weeks since prior and no concurrent corticosteroids (at doses &gt; the
             equivalent of 5 mg/day prednisone) for &gt; 2 weeks total

          -  No prior or concurrent sodium fluoride (at daily doses ≥ 5 mg/day) for &gt; 1 month

          -  More than 12 months since prior and no concurrent anabolic steroids

          -  More than 6 months since prior treatment, either investigational or not, for the
             prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin D])

          -  No concurrent raloxifene

          -  Concurrent therapeutic intervention for osteoporosis comprising bisphosphonates
             allowed

          -  Concurrent warfarin allowed provided it is given for ≤ 4 weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Aebi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Decensi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Oncology at Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Beata Vergine</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH-6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>July 26, 2012</last_update_submitted>
  <last_update_submitted_qc>July 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

